Please select the option that best describes you:
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
For instance, after initial treatment with IV alemtuzumab, with or without pentostatin
For instance, after initial treatment with IV alemtuzumab, with or without pentostatin